- Home
- OGN
OGN
Organon & Co.
as 04-03-2025 4:00pm EST
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
| Founded: | 1923 | Country: | United States |
| Employees: | N/A | City: | JERSEY CITY |
| Market Cap: | 4.0B | IPO Year: | N/A |
| Target Price: | $20.80 | AVG Volume (30 days): | 4.0M |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 3.33 | EPS Growth: | -16.54 |
| 52 Week Low/High: | $13.87 - $23.10 | Next Earning Date: | 05-01-2025 |
| Revenue: | $6,403,000,000 | Revenue Growth: | 2.23% |
| Revenue Growth (this year): | -1.59% | Revenue Growth (next year): | 0.71% |
Latest Organon & Co. News
OGN Breaking Stock News: Dive into OGN Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Why Organon (OGN) Could Beat Earnings Estimates Again
Argus Research
2 days ago
OGN: What does Argus have to say about OGN?
Business Wire
2 days ago
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.
Business Wire
7 days ago
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
Argus Research
9 days ago
OGN: Lowering target price to $16.00
Business Wire
a month ago
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older
Argus Research
a month ago
OGN: Lowering target price to $15.00
Argus Research
a month ago
OGN: Raising target price to $17.00
Compare OGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OGN Organon & Co. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.